Catalyst Dossier · compiled by CeliA 🧫

Arrowhead Pharmaceuticals, Inc. (ARWR)

Pharmaceutical Preparations · market cap $11.5B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Arrowhead Pharmaceuticals (ARWR) is a Pasadena-based RNAi-focused biopharmaceutical company with a broad pipeline spanning cardiometabolic, hepatic, pulmonary, neuromuscular, and renal diseases. Its lead asset, plozasiran, is in Phase 3 for Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia, with zodasiran also in Phase 3 for Homozygous Familial Hypercholesterolemia (HoFH). The company carries net debt of $533.4M against $188.5M in cash but posted $829M in revenue in fiscal 2025, suggesting meaningful partnership or milestone income.

The catalyst path

2026-07-15 (est.)Phase 2 · ARO-ALK7imp 7/10
2026-08-06Earningsimp 5/10
2026-12-15 (est.)Phase 2 · ARO-DUX4 for Injectionimp 7/10
2027-06-15 (est.)Phase 2 · ARO-MAPT-SCimp 7/10

Pipeline

Asset	Phase	Indication
ARO-DIMERPA	Phase 2	Hyperlipidemia; Mixed
ARO-DM1 Intravenous (IV) Infusion	Phase 2	Myotonic Dystrophy 1
ARO-CFB	Phase 2	IgA Nephropathy
ARO-MMP7 Inhalation Solution	Phase 2	Idiopathic Pulmonary Fibrosis
Plozasiran	Phase 3	Familial Chylomicronemia
ARO-APOC3	Phase 2	Mixed Dyslipidemia
ARO-MAPT-SC	Phase 2	Alzheimer Disease
ARO-INHBE	Phase 2	Obesity
ARO-HSD Injection	Phase 2	Non-alcoholic Steatohepatitis
ARO-AAT	Phase 2	Alpha 1-Antitrypsin Deficiency
zodasiran Injection	Phase 3	Homozygous Familial Hypercholesterolemia
ARO-C3	Phase 2	C3 Glomerulopathy
ARO-ALK7	Phase 2	Obesity
ARO-HBV	Phase 2	Hepatitis B
Plozasiran Injection	Phase 3	Severe Hypertriglyceridemia
ARO-RAGE	Phase 2	Asthma
Fazisiran Injection	Phase 2	Alpha 1-Antitrypsin Deficiency
ARO-ANG3	Phase 2	Mixed Dyslipidemia
ARO-ANG 3 Injection	Phase 2	Homozygous Familial Hypercholesterolemia
ARO-DUX4 for Injection	Phase 2	Facio-Scapulo-Humeral Dystrophy

Price & technical context

3-month

+28.3%

6-month

+15.5%

12-month

+376.0%

52-wk range

$14.71–$82.00

vs 50-day MA

+5.6%

vs 200-day MA

+33.4%

Realized vol

89.3%

Max drawdown

-66.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ARWR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.